ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer and Adolor are collaborating on the development and commercialization of two novel compounds, ADL5859 and ADL5747, for the treatment of pain. Both are proprietary δ-opioid receptor agonists identified by Adolor that, according to the firms, have the potential to treat a range of inflammatory, neuropathic, and acute pain conditions. Adolor will receive an upfront payment of $30 million and may also receive up to $232.5 million in milestone payments. ADL5859 is in Phase II clinical development for treating pain associated with rheumatoid arthritis and dental surgery. Adolor expects to begin Phase I testing of ADL5747 early next year for an unspecified ailment.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter